Immunic (IMUX) Akcija Цена
Immunic Цена
Medijana analitičke ciljane cene je 20,50 USD, odnosno iznad trenutnu cenu za 169,7 %. Od 19 analitičara 18 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Immunic
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Immunic poslovni model i analiza akcije
Često postavljana pitanja o akciji Immunic
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 22,13 USD za akciju Immunic (medijana: 20,50 USD), što znači +191,2 % u odnosu na poslednju cenu. Konsenzus se zasniva na 19 ocena.
19 analitičara trenutno ocenjuje akciju Immunic: 18 preporučuje kupovinu, 1 držanje i 0 prodaju. Za 2026 analitičari očekuju da Immunic ostvari prihod 12,50 М USD i zaradu po akciji -35,92 USD.
Po trenutnom kursu akcija Immunic kotira 6,79 EUR (7,60 USD).
Akcija Immunic (IMUX) kotira na 5 berze, uključujući: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
očekivana prihod od Immunic je 12,50 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Immunic je -432,40 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Immunic je trenutno -0,21. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Immunic.
Odnos cene i prihoda (KUV) za Immunic je trenutno 7,32. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Immunic.
Eulpool score kvaliteta za Immunic je 5/10.
ISIN za Immunic je US4525EP1011. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Immunic je A2PHD4. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Immunic je IMUX. Simbol tikera se koristi za trgovinu akcijama Immunic na berzanskom tržištu.
Immunic акција
Immunic Peer grupa
Immunic Тикер
Immunic FIGI
Sve ključne metrke i detaljne analize Immunic u dubinskoj analizi
Naša analiza akcija za akciju Immunic uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Immunic. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: